Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type

Neuroscience

Volumn 167, Issue 4, 2010, Pages 1183-1191

  Roessner, V ^a,b   Sagvolden, T ^c   DasBanerjee, T ^d   Middleton, F A ^d   Faraone, S V ^d   Walaas, S I ^c   Becker, A ^a   Rothenberger, A ^a   Bock, N ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Attention deficit hyperactivity disorder; Development; Dopamine transporter; Methylphenidate; Spontaneously hypertensive rats; Wistar Kyoto rats

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; BINDING ASSAY; CONTROLLED STUDY; DENSITY; DEVELOPMENTAL STAGE; DRUG MECHANISM; GENE EXPRESSION; GENE FUNCTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PREPUBERTY; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; WISTAR KYOTO RAT;

ANIMALS; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; MALE; METHYLPHENIDATE; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RNA, MESSENGER; SPECIES SPECIFICITY; TIME FACTORS;

EID: 77952552301     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.02.073     Document Type: Article

References (53)

1. Andersen S.L., Navalta C.P. Altering the course of neurodevelopment: a framework for understanding the enduring effects of psychotropic drugs. Int J Dev Neurosci 2004, 22:423-440.
2. Carey M.P., Diewald L.M., Esposito F.J., Pellicano M.P., Gironi Carnevale U.A., Sergeant J.A., Papa M., Sadile A.G. Differential distribution, affinity and plasticity of dopamine D-1 and D-2 receptors in the target sites of the mesolimbic system in an animal model of ADHD. Behav Brain Res 1998, 94:173-185.
3. Cheng J.Y., Chen R.Y., Ko J.S., Ng E.M. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl) 2007, 194:197-209.
4. Congdon E., Lesch K.P., Canli T. Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:27-32.
5. DasBanerjee T., Middleton F.A., Berger D.F., Lombardo J.P., Sagvolden T., Faraone S.V. A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1554-1563.
6. Dresel S., Krause J., Krause K.H., LaFougere C., Brinkbaumer K., Kung H.F., Hahn K., Tatsch K. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000, 27:1518-1524.
7. Feron F.J., Hendriksen J.G., van Kroonenburgh M.J., Blom-Coenjaerts C., Kessels A.G., Jolles J., Weber W.E., Vles J.S. Dopamine transporter in attention-deficit hyperactivity disorder normalizes after cessation of methylphenidate. Pediatr Neurol 2005, 33:179-183.
8. Galineau L., Kodas E., Guilloteau D., Vilar M.P., Chalon S. Ontogeny of the dopamine and serotonin transporters in the rat brain: an autoradiographic study. Neurosci Lett 2004, 363:266-271.
9. Gau S.S., Chen S.J., Chou W.J., Cheng H., Tang C.S., Chang H.L., Tzang R.F., Wu Y.Y., Huang Y.F., Chou M.C., Liang H.Y., Hsu Y.C., Lu H.H., Huang Y.S. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 2008, 69:131-140.
10. Gerasimov M.R., Franceschi M., Volkow N.D., Gifford A., Gatley S.J., Marsteller D., Molina P.E., Dewey S.L. Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000, 295:51-57.
11. Gorman E.B., Klorman R., Thatcher J.E., Borgstedt A.D. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006, 45:808-816.
12. Grund T., Lehmann K., Bock N., Rothenberger A., Teuchert-Noodt G. Influence of methylphenidate on brain development-an update of recent animal experiments. Behav Brain Funct 2006, 2:2.
13. Haycock J.W., Becker L., Ang L., Furukawa Y., Hornykiewicz O., Kish S.J. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J Neurochem 2003, 87:574-585.
14. Hoare P., Remschmidt H., Medori R., Ettrich C., Rothenberger A., Santosh P., Schmit M., Spender Q., Tamhne R., Thompson M., Tinline C., Trott G.E. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry 2005, 14:305-309.
15. Hurtig T., Ebeling H., Taanila A., Miettunen J., Smalley S.L., McGough J.J., Loo S.K., Jarvelin M.R., Moilanen I.K. ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms. J Am Acad Child Adolesc Psychiatry 2007, 46:1605-1613.
16. Husson I., Mesples B., Medja F., Leroux P., Kosofsky B., Gressens P. Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 2004, 125:163-170.
17. Johansen E.B., Killeen P.R., Russell V.A., Tripp G., Wickens J.R., Tannock R., Williams J., Sagvolden T. Origins of altered reinforcement effects in ADHD. Behav Brain Funct 2009, 5:7.
18. Johansen E.B., Killeen P.R., Sagvolden T. Behavioral variability, elimination of responses, and delay-of-reinforcement gradients in SHR and WKY rats. Behav Brain Funct 2007, 3:60.
19. Johnson K.A., Wiersema J.R., Kuntsi J. What would Karl Popper say?. Are current psychological theories of ADHD falsifiable?. Behav Brain Funct 2009, 5:15.
20. Kollins S., Greenhill L., Swanson J., Wigal S., Abikoff H., McCracken J., Riddle M., McGough J., Vitiello B., Wigal T., Skrobala A., Posner K., Ghuman J., Davies M., Cunningham C., Bauzo A. Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS). J Am Acad Child Adolesc Psychiatry 2006, 45:1275-1283.
21. Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 2008, 8:611-625.
22. Krause K.H., Dresel S.H., Krause J., Kung H.F., Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000, 285:107-110.
23. Kuczenski R., Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 2005, 57:1391-1396.
24. Larsson H., Lichtenstein P., Larsson J.O. Genetic contributions to the development of ADHD subtypes from childhood to adolescence. J Am Acad Child Adolesc Psychiatry 2006, 45:973-981.
25. Lavalaye J., Booij J., Reneman L., Habraken J.B., van Royen E.A. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000, 27:867-869.
26. Meng S.Z., Ozawa Y., Itoh M., Takashima S. Developmental and age-related changes of dopamine transporter, and dopamine D1 and D2 receptors in human basal ganglia. Brain Res 1999, 843:136-144.
27. Mill J., Sagvolden T., Asherson P. Sequence analysis of Drd2, Drd 4, and Dat1 in SHR and WKY rat strains. Behav Brain Funct 2005, 1:24.
28. Moll G.H., Hause S., Ruther E., Rothenberger A., Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001, 11:15-24.
29. Moll G.H., Mehnert C., Wicker M., Bock N., Rothenberger A., Ruther E., Huether G. Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res 2000, 119:251-257.
30. Resch F., Rothenberger A. Attention deficit hyperactivity disorder and stimulants-new evidence-based objectivity is helpful. Z Kinder Jugendpsychiatr Psychother 2002, 30:159-161.
31. Russell V.A., Sagvolden T., Johansen E.B. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 2005, 1:9.
32. Sagvolden T., Dasbanerjee T., Zhang-James Y., Middleton F., Faraone S. Behavioral and genetic evidence for a novel animal model of attention-deficit/hyperactivity disorder predominantly inattentive subtype. Behav Brain Funct 2008, 4:56.
33. Sagvolden T., Johansen E.B., Aase H., Russell V.A. A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 2005, 28:397-419. discussion: 419-368.
34. Sagvolden T., Johansen E.B., Woien G., Walaas S.I., Storm-Mathisen J., Bergersen L.H., Hvalby O., Jensen V., Aase H., Russell V.A., Killeen P.R., Dasbanerjee T., Middleton F.A., Faraone S.V. The spontaneously hypertensive rat model of ADHD-the importance of selecting the appropriate reference strain. Neuropharmacology 2009, 57:619-626.
35. Shaw P., Sharp W.S., Morrison M., Eckstrand K., Greenstein D.K., Clasen L.S., Evans A.C., Rapoport J.L. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am J Psychiatry 2009, 166:58-63.
36. Sidak Z. Rectangular confidence regions for means of multivariate normal distributions. J Am Stat Assoc 1967, 62:626-633.
37. Solanto M.V., Gilbert S.N., Raj A., Zhu J., Pope-Boyd S., Stepak B., Vail L., Newcorn J.H. Neurocognitive functioning in AD/HD, predominantly inattentive and combined subtypes. J Abnorm Child Psychol 2007, 35:729-744.
38. Spencer T.J., Biederman J., Madras B.K., Faraone S.V., Dougherty D.D., Bonab A.A., Fischman A.J. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry 2005, 57:1293-1300.
39. SPSS for Windows, version release 11.0 2001, SPSS, SPSS Inc, Chicago.
40. Swanson J.M., Kinsbourne M., Nigg J., Lanphear B., Stefanatos G.A., Volkow N., Taylor E., Casey B.J., Castellanos F.X., Wadhwa P.D. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 2007, 17:39-59.
41. Swanson J.M., Volkow N.D. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev 2003, 27:615-621.
42. Tarazi F.I., Tomasini E.C., Baldessarini R.J. Postnatal development of dopamine and serotonin transporters in rat caudate-putamen and nucleus accumbens septi. Neurosci Lett 1998, 254:21-24.
43. Taylor E., Dopfner M., Sergeant J., Asherson P., Banaschewski T., Buitelaar J., Coghill D., Danckaerts M., Rothenberger A., Sonuga-Barke E., Steinhausen H.C., Zuddas A. European clinical guidelines for hyperkinetic disorder-first upgrade. Eur Child Adolesc Psychiatry 2004, 13(Suppl 1):I7-I30.
44. van West D., Claes S., Deboutte D. Differences in hypothalamic-pituitary-adrenal axis functioning among children with ADHD predominantly inattentive and combined types. Eur Child Adolesc Psychiatry 2009, 18:543-553.
45. Vles J.S., Feron F.J., Hendriksen J.G., Jolles J., van Kroonenburgh M.J., Weber W.E. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 2003, 34:77-80.
46. Walitza S., Melfsen S., Herhaus G., Scheuerpflug P., Warnke A., Muller T., Lange K.W., Gerlach M. Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood. J Neural Transm Suppl 2007, 72:311-315.
47. Wargin W., Patrick K., Kilts C., Gualtieri C.T., Ellington K., Mueller R.A., Kraemer G., Breese G.R. Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983, 226:382-386.
48. Watanabe Y., Fujita M., Ito Y., Okada T., Kusuoka H., Nishimura T. Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 1997, 38:470-474.
49. Wehmeier P.M., Schacht A., Rothenberger A. Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years. Child Adolesc Psychiatry Ment Health 2009, 3:3.
50. Weiss M., Worling D., Wasdell M. A chart review study of the inattentive and combined types of ADHD. J Atten Disord 2003, 7:1-9.
51. Wilens T.E., Klint T., Adler L., West S., Wesnes K., Graff O., Mikkelsen B. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct 2008, 4:24.
52. Williams J., Sagvolden G., Taylor E., Sagvolden T. Dynamic behavioural changes in the spontaneously hyperactive rat: part 1. Control by place, timing, and reinforcement rate. Behav Brain Res 2009, 198:273-282.
53. Winterstein A.G., Gerhard T., Shuster J., Zito J., Johnson M., Liu H., Saidi A. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008, 42:24-31.